Compare iShares Core MSCI EAFE ETF (IEFA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? iShares Core MSCI EAFE ETF trades at $95.53 (market cap $188.94B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 25.1× Spyre Therapeutics Inc. Common Stock's market cap, and iShares Core MSCI EAFE ETF is more actively traded (6,200,262 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IEFA | SYRE | |
|---|---|---|
Market Cap | $188.94B | $7.52B |
Volume | 6,200,262 | 1,441,031 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $108.92 |
52-Week Low | $85.06 | $22.18 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA, the iShares Core MSCI EAFE ETF, trades at $96.64, up 0.48% on the day, while technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF provides exposure to developed markets outside North America, managing $196 billion in assets. Recent news highlights its size advantage and higher dividend yield compared to peers, though some competitors have shown stronger recent returns.
The outlook for IEFA is mixed, with bearish technicals offset by its low-cost, diversified international exposure. Opportunities include defensive shifts in investor flows away from concentrated U.S. tech, while risks involve underperformance versus broader global funds and capped upside in strategies like covered calls on the ETF.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
